Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in patients with colorectal cancer
Phase 1
- Conditions
- Patients with metastatic colorectal cancerTherapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Registration Number
- CTIS2024-515908-39-00
- Lead Sponsor
- Centr Georges Francois Leclerc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method